AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$EOLS

MOATAZEDI DAVID sold $950K of EOLS

MOATAZEDI DAVID (See Remarks) sold 105,108 shares of Evolus, Inc. (EOLS) at $9.04 ($0.95M total) on 2026-09-02.

Original reporting
SEC EDGAR · MOATAZEDI DAVID
Published Sep 4, 2026, 11:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EOLS
Bearish
medium confidence
Mentioned
$EOLS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EOLSBearishLow
01

Why it matters

Provides fresh data on insider sentiment for Evolus, useful for short-term trading decisions.

02

Market read

New insider sale information may influence short-term price action.

03

What to watch

The insider retains a substantial stake of 499,592 shares, indicating continued confidence.

Relevance 5/10Novelty 4/10Timing: after market Sep 4, 2026

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$EOLSBearishMedium confidence
Context

Officer/director sold 105,108 shares for $950K on Sep 2, 2026.

Expected impact

Modest downside pressure in the next few trading sessions.

Evidence & confidence

Sale size is modest relative to holdings, but the insider is a director, which can influence perception.

Market effects

Sector

Minimal impact on the cosmetics/beauty sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Evolus, Inc.

    US-listed cosmetics company (ticker EOLS).

  • Insider
    Moatazedi David

    Officer and director of Evolus who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EOLS insider trading history →

Related articles

OCT 2
$EOLSMed

Evolus (EOLS) Shares Fall After FDA Warning on Jeuveau Instagram

Evolus Inc (EOLS) shares fell after the FDA issued a warning over a misleading Instagram post about its product Jeuveau. The company must submit a corrective action plan within 15 days. Evolus's P/S ratio is 1.49, below its historical median, and it has a GF Score of 74/100. Insiders have sold $1.8 million in shares over the past year. Jeuveau accounts for over 90% of the company's revenue, which totaled $316.5 million over the trailing twelve months.

gurufocus.com3 min
OCT 2
$EOLSHigh

FDA Flags Evolus (EOLS) for Misleading Jeuveau Promotion on Inst

The FDA warned Evolus (EOLS) for misleading Jeuveau promotion on Instagram, citing public health risks. Evolus's P/S ratio is 1.49, below its historical median of 3.2x, reflecting market uncertainty. The company has a GF Score of 74/100, with strong growth but weak profitability and financial strength. Insiders sold $1.8M in shares over the past year, while institutional investors show mixed interest.

gurufocus.com2 min
SEP 9
$EOLSMed

Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future

Evolus (EOLS) reported Q2 2026 revenue of $84.1M, up 21% YoY, and positive Adjusted EBITDA of $4.7M. The company raised full-year revenue guidance to $330M-$337M and adjusted gross profit margin guidance to 67.0%-67.5%. Evolus expanded its customer base and loyalty program, while investing in new product launches and partnerships.

yahoo.com2 min